Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study

Stefanie V. Junk,Alisa Förster,Gunnar Schmidt,Martin Zimmermann,Birthe Fedders,Bernd Haermeyer,Anke K. Bergmann,Anja Möricke,Gunnar Cario,Bernd Auber,Martin Schrappe,Christian P. Kratz,Martin Stanulla
DOI: https://doi.org/10.1038/s41375-024-02173-2
2024-02-28
Leukemia
Abstract:Leukemia, Published online: 27 February 2024; doi:10.1038/s41375-024-02173-2 Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study
oncology,hematology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: among children with acute lymphoblastic leukemia (ALL), which germline genetic variations are related to the occurrence of secondary malignant neoplasms (SMN). Specifically, the researchers hope to determine whether the genetic variations in these genes are related to the increased risk of SMN after treatment in ALL patients by analyzing 159 selected cancer - susceptibility genes (CPG). ### Research Background - **Severity of the Problem**: Although most children with ALL can be cured by intensive combination chemotherapy, up to 10% of patients will develop into SMN within 20 years, and the cure rate of these patients is usually low. - **Research Needs**: Therefore, it is necessary to identify patients at risk of SMN early and deeply understand their underlying pathophysiological mechanisms, so as to develop preventive measures. ### Research Methods - **Sample Selection**: The study included patients aged 1 to 22 years diagnosed with ALL, who participated in the European AIEOP - BFM ALL 2000 multi - center clinical trial. - **Matching Design**: A case - control study design was used to analyze the germline DNA in bone marrow samples from 75 SMN patients and 148 control patients. - **Gene Selection**: Candidate genes include those based on previous work or recommended by Byrjalsen et al. - **Data Analysis**: Statistical analysis was carried out using software such as SAS, SPSS and R. ### Main Findings - **Variation Frequency**: 31 significant variations were found in 22 genes. Among them, 17 (6 potentially pathogenic and 11 pathogenic) variations were found in 16 (21%) SMN patients, while 14 (9 potentially pathogenic and 5 pathogenic) variations were found in 14 (9%) control patients. - **Specific Gene Variations**: Some genes such as ATM, TP53, A2ML1, MSH6 and PMS2 only had variations in SMN patients. - **Risk Assessment**: Patients carrying these gene variations had a 2.2 - fold increased risk of SMN (OR = 2.21, 95% CI = 0.989 – 4.944, P = 0.053). ### Conclusions - **Main Conclusions**: The frequency of (potentially) pathogenic germline CPG variations in SMN patients is 2.0 times higher than that in the control group, and the presence of these variations increases the SMN risk by 2.2 times. - **Future Directions**: Although most SMN patients (> 70%) do not have harmful variations in the selected candidate genes, future research can further improve the understanding and prediction of SMN risk through non - targeted whole - exome analysis and more focused use of genetic information. Through this study, the authors hope to provide an important basis for the long - term follow - up of ALL patients and the development of new treatment strategies, especially for those patients at risk of SMN.